A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Milatuzumab-doxorubicin conjugate (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 22 Jan 2014 Status changed from suspended to completed according to ClinicalTrials.gov record .
- 18 Jun 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 17 Nov 2012 Planned number of patients changed from 42 to 144.